Central SensitisationEarly Phase 1QUROCNCT03944889
Quantitative Ultrasound Response of Capsaicin
A Early Phase 1 study testing Capsaicin, Delsys Trigno Galileo System and Cadwell Sierra Wave in people with Central Sensitisation, run by Toronto Rehabilitation Institute at 1 site in Canada.
Trial summary
Central Sensitization is an aspect of chronic pain and is associated with over-excitability of the central nervous system. Central Sensitization normally presents itself with other chronic syndromes such as Myofascial Pain Syndrome, so it is difficult to separate the characteristics of the two. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Central Sensitisation
- What is being tested?
- Capsaicin, Delsys Trigno Galileo System and Cadwell Sierra Wave
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteCanada
- Study dates
- 1 Jul 2019to 1 Dec 2020
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- healthy with no past medical history
- a visual analogue score below 3 indicating low pain severity, ideally who complain of no pain
- right or left handed
- normal body mass index
- have sufficient knowledge of the English language to provide informed consent and understand the protocols
- agree to sign a consent form.
Who cannot join
- history of pain
- detectable myofascial trigger points upon physical examination
- history of pain related disturbances such as poor sleep
- cognitive disturbances, psychiatric disorders
- history of general medical disorder that may affect the outcome of the study such as diabetes mellitus
- history of cervical radiculopathies
- history of inflammatory arthropathy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Quantitative Response of Healthy Muscle Following the Induction of Capsaicin
Central Sensitization is an aspect of chronic pain and is associated with over-excitability of the central nervous system. Central Sensitization normally presents itself with other chronic syndromes such as Myofascial Pain Syndrome, so it is difficult to separate the characteristics of the two. The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin, a chilli pepper extract, induces a regional change in ultrasound texture features of the targeted muscle, or the muscles in that are in close proximity. This regional change will be accompanied by electromyography (EMG) recordings to confirm the presence of abnormality. Topical capsaicin and injectable capsaicin will be applied at three different concentrations, 0ug(placebo effect),50ug and 100ug.
Research Questions:
Read more
Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles? Is this regional change confirmed by abnormality of motor unit firing rates or EMG amplitudes? Is the response dose dependent? Does the induced central sensitization cause a change in force steadiness?
Experimental Protocol:
The physician on site will apply surface and intramuscular EMG sensors to the trapezius. A goniometer will be placed on the subjects arm to detect position. Following this, an ultrasound image of the trapezius, supraspinatus and infraspinatus will be taken.The participant will perform an increasing and decreasing contraction.The subject will then have capsaicin injected into their trapezius or applied onto their skin. The exercise and measurements will then be repeated. The ultrasound will be acquired by the Sonosite ultrasound system. The EMG data will be acquired by the Delsys Trigno EMG system for the surface EMG and the Cadwell Sierra Wave system for the intramuscular EMG. The data will be processed through Delsys EMGworks software and MATLAB. Texture features of the pre and post injection ultrasound images will be compared. Decomposition of motor units will allow for the analysis of motor unit action potential firing rate and amplitudes. Analysis of force steadiness will also be calculated via the goniometer.
Overall, the findings from this study should present preliminary evidence to inform central sensitization's effects on regional muscle structure changes, functional changes and motor unit activity.
Read the detailed description
Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder primarily characterized by myofascial trigger points (MTrP). There is limited knowledge on the pathophysiology and mechanisms underlying MTrP and its development. Ultrasound investigations that have been performed on trigger points can differentiate between active and latent trigger points, but have not characterized the central sensitization aspect of them. The electromyography (EMG) investigations of central sensitization that have been performed mostly use hypertonic saline to induce hyperalgesia, and have demonstrated conflicting results. Central sensitization has been proposed as the primary mechanism underlying MTrP development. Central sensitization is associated with hyperexcitability of neuronal responses to normal or noxious stimuli. There is a need for a study that quantifies regional central sensitization using ultrasound to measure the changing structure, and electromyography to measure specific motor unit activity responses in the muscle.
Purpose The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin induces a change in the structural integrity of the affected muscle, and determine if the motor unit frequency and amplitudes change within that region. Central sensitization will be induced using topical capsaicin and injectable capsaicin at three different concentrations. This is an exploratory trial that aims to provide preliminary evidence on whether central sensitization is a direct cause of taut band and MTrP development.
Our specific research questions are followings:
- Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles?
- Does capsaicin induced sensitization elicit a change in motor unit action potential(MUAP) amplitude by approximately 20 to 25% within the region of experimentally induced central sensitization or in the region of texture feature changes? Our hypothesis for this portion of the study is that sensitization modifies the anterior horn cell activity which will be measured by the amplitude of the potentials.
- Does capsaicin induced sensitization elicit continuous electrical activity as observed in MTrPs? This tests the hypothesis that sensitization creates the presence of continuous low amplitude action potentials.
- Does capsaicin induced sensitization influence the rate of recruitment of motor units in the muscle within the region induced? Does this occur within the regions identified by the changes in texture features? The recruitment of motor units is normally expected to follow the Henneman size principle.[20-23] Our hypothesis for this portion of the study is that sensitization will cause an aberration in recruitment. If this is demonstrated, then there is modification of the normal processing at both dorsal and ventral horns of the spinal cord.
- Is there a location dependent EMG response to capsaicin induced sensitization? In other words, do the texture features or EMG responses from muscles that lie anatomically distant from the location of the site of intramuscular capsaicin injection have changes from their baseline calculations? This would test the hypothesis that type III and IV afferents have an influence on the anterior horn cells that lie distant to the ones that are supplying muscle fibers in the vicinity of the stimulated sensory afferents.
- Is there a dose dependent EMG response at motor units to capsaicin induced sensitization? Here, the hypothesis of causality will be assessed in a preliminary manner. If there is a relationship then further experiments that more thoroughly assess causality will be needed.
This proposed study is a single centered, factorial, randomized placebo-controlled trial with two independent variables, depth of capsaicin application(3 levels) and dose of capsaicin(3 levels), for a total of 6 treatment arms and three control groups.The first between groups variable will be topical capsaicin application, injectable(intrafascial) and injectable(intramuscular) capsaicin injection. Within each partition, there will be three treatments: control, 50 micrograms, 100 micrograms. The control group will receive a topical skin lotion that is inert and has no sensitization effect. An equal number of participants will be allocated to each of the six treatment groups using an electronic randomization generator. Block randomization will be used to ensure equal allotment into each group.
Capsaicin Application and Injection Capsaicin will be applied directly to the region of the innervation zone at the muscle belly to sensitize the neurons within the region of taut band development. Topical and intramuscular capsaicin will be used. The capsaicin formula will be compounded by a registered pharmacist. Topical capsaicin will be delivered in a cream and injectable capsaicin will be intermixed with saline prior to injection. The control group in the topical capsaicin arm will be treated with the cream base used during the experiment without added capsaicin and the injection arm will be injected with saline. A trained medical professional on the research team will apply the topical capsaicin or topical placebo treatments. The region of topical application will measure 5cm squared in the dermatome zone location to cover an area of approximately 25cm2. A trained physician in physical medicine and rehabilitation will deliver injectable capsaicin using a 27-gauge needle at the location of the superior fascia of the upper trapezius muscle with ultrasound guidance. Intramuscular capsaicin will also be injected using ultrasound guidance to avoid the superior or inferior fascia.
To confirm the presence of central sensitization, brush allodynia will be used to detect mechanical hyperalgesia outside the region of primary nociception. The size of the region of secondary hyperalgesia will be measured to characterize the extent of central sensitization. This will be accomplished using a tape measure and the perpendicular dimensions of the region of secondary hyperalgesia will be recorded in square centimeters.
Experimental Protocol The anatomical location for ultrasound probe and electrode placement will be identified for each participant. The ultrasound probe will be placed on 3 muscles: the trapezius, the supraspinatus, and the infraspinatus. Two ultrasonic pictures will be taken of each. The area will then be cleaned with alcohol and water. The Delsys Galileo sensor, and the intramuscular needle electrode will be placed directly on the trapezius' identified area. Participants will be asked to gently contract their trapezius muscle. They will be instructed to perform a gradually increasing contraction in isometric condition, in a controlled manner. They will hold this contraction at 30% of their maximal voluntary contraction, and then perform a gradually decreasing contraction to rest. This will be performed four times for each type of study intervention and before as well as after each intervention, namely topical control cream, topical capsaicin at 50ug and 100 ug, injection of the superior aspect of the superior fascia followed by intramuscular injection with these two concentrations of capsaicin. The placement of these latter will be verified by ultrasound guidance. The intramuscular needle will then be removed and participants will be bandaged and cared for appropriately by the expert physician performing the experiment. Participants will be re-examined to determine if there were any adverse effects from the experimental procedures. If any occurred, then these will be carefully managed by the medical members of the research team and recorded. Participants will be asked to remain at the lab for an additional 30 minutes to ensure they are well prior to leaving.
Ultrasound Analysis Texture analysis will be performed using MATLAB and the image and signal processing toolbox. Analyses will include first order parameters such as mean and standard deviation of the pixel level values, as well as second order parameters, which provide details on the spatial distribution of pixel values. These include co-occurance and run-length matrices, local binary pattern and blob analysis.
EMG Analysis The following parameters will be analyzed: the firing times and frequency of individual motor units, motor unit action potential amplitude and shapes, the root mean square value (RMS) of each channel and of the entire signal, the coefficient of variation for force steadiness, and the centroid of the EMG signal in the cranial-caudal and the medial-lateral directions. These procedures will be repeated for each contraction.
The results of this study should provide insight into the structural changes and motor changes at the region of sensitization, as well as in adjacent muscles.This will provide further insight as to whether structural changes are accompanied by motor changes within the same region, and inform further investigations into the pathophysiology of myofascial pain.
The full study protocol and statistical analysis plan is submitted in the documents section.
- Conditions
- Central Sensitisation
- Being tested
- Capsaicin, Delsys Trigno Galileo System, Cadwell Sierra Wave, Sonosite Ultrasound Machine, Goniometer
- Keywords
- MUAP- Motor Unit Action Potential, RMS- Root Mean Square, US-Ultrasound
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CapsaicinDrug
Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
Delsys Trigno Galileo SystemDevice
This device is a wireless surface EMG device.
Cadwell Sierra WaveDevice
Intramuscular EMG recording machinery
Sonosite Ultrasound MachineDevice
Ultrasound System
GoniometerDevice
A device to measure angular position
| Study group | Role | What they receive |
|---|---|---|
| Placebo Topical | Placebo comparator | Placebo Cream, applied topically to trapezius muscle Receives: Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| Low Dose, Topical | Active comparator | Capsaicin Cream- low dosage, applied topically to trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| High Dose, Topical | Active comparator | Capsaicin Cream- higher dosage, applied topically to trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| Placebo, Intrafascial | Placebo comparator | Injection placebo(saline)- injected intrafascially into trapezius Receives: Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| Low Dose, Intrafacial | Active comparator | Injection Capsaicin formulation low dose- injected intrafascially into trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| High Dose, Intrafascial | Active comparator | Injection Capsaicin formulation higher dose- injected intrafascially into trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| Placebo, Intramuscular | Placebo comparator | Injection placebo (saline) - injected intramuscularly into trapezius Receives: Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| Low Dose, Intramuscular | Active comparator | Injection Capsaicin formulation low dose - injected intramuscularly into trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
| High Dose, Intramuscular | Active comparator | Injection Capsaicin formulation higher dose - injected intramuscularly into trapezius Receives: Drug: Capsaicin; Device: Delsys Trigno Galileo System; Device: Cadwell Sierra Wave; Device: Sonosite Ultrasound Machine; Device: Goniometer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor Unit Action Potential Firing Rate
Firing rate will be determined using EMGworks software and compared with baseline firing rates.
Measured: up to 6 months
Root Mean Square EMG values
Root mean square values will be compared with baseline values using EMGworks software.
Measured: up to 6 months
Coefficient of Variation- Force steadiness
Force steadiness will be measured by the coefficient of variation (standard deviation/mean) using EMGworks software, validated through the goniometer measurements
Measured: up to 6 months
Motor Unit Action Potential Amplitudes
Amplitudes will be measured from the overall amplitude difference from baseline for each motor unit using EMGworks software
Measured: up to 6 months
Centroid of Frequency Spectrum
Centroid frequency will be measured and the frequency shift of the signal will be compared with baseline. Measured using EMGworks software
Measured: up to 6 months
Texture Feature Analysis
91 features will be extracted using MATLAB, then a reduction of variables will be performed using principal component analysis. The experimental data will be compared with baseline results.
Measured: up to 6 months
Secondary outcomes (1)
Severity of pain
Pain, or burning sensation measured by the visual analogue scale(0-no pain to 10-worst pain imaginable)
Measured: up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2019
- Study start1 Jul 2019
- Primary completion1 Jul 2020
- Study completion1 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (45)Papers the sponsor has linked to this study.
- Other trials for Central SensitisationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- A single-centered, factorial, randomized, placebo-controlled trial with two independent variables (dosage and depth of application).
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Toronto Rehabilitation Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dinesh Kumbhare, Toronto Rehabilitation Institute
- Investigators
- Dinesh M Kumbahre, MD,PhD, Principal investigator, Toronto Rehabilitation Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03944889
- Sponsor's protocol ID
- CapsaicinUltrasound
- Acronym
- QUROC
- Status last verified
- Dec 2020
- First submitted
- 3 May 2019
- Last updated
- 3 Dec 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
- Individual data sharing
- No: The University Health Network has a high importance on patient confidentiality. For ethics approval, this was complied with these standards, upholding the patient confidentiality standard at UHN.
Publications
Srbely JZ. New trends in the treatment and management of myofascial pain syndrome. Curr Pain Headache Rep. 2010 Oct;14(5):346-52. doi: 10.1007/s11916-010-0128-4.
PubMed 20607458Masuda T, Sadoyama T. Distribution of innervation zones in the human biceps brachii. J Electromyogr Kinesiol. 1991 Jun;1(2):107-15. doi: 10.1016/1050-6411(91)90004-O.
PubMed 20870500Barbero M, Cescon C, Tettamanti A, Leggero V, Macmillan F, Coutts F, Gatti R. Myofascial trigger points and innervation zone locations in upper trapezius muscles. BMC Musculoskelet Disord. 2013 Jun 8;14:179. doi: 10.1186/1471-2474-14-179.
PubMed 23758854Melzack R, Stillwell DM, Fox EJ. Trigger points and acupuncture points for pain: correlations and implications. Pain. 1977 Feb;3(1):3-23. doi: 10.1016/0304-3959(77)90032-X.
PubMed 69288Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil. 1998 Jul;79(7):863-72. doi: 10.1016/s0003-9993(98)90371-9.
PubMed 9685106Gerwin RD, Dommerholt J, Shah JP. An expansion of Simons' integrated hypothesis of trigger point formation. Curr Pain Headache Rep. 2004 Dec;8(6):468-75. doi: 10.1007/s11916-004-0069-x.
PubMed 15509461Bron C, Dommerholt JD. Etiology of myofascial trigger points. Curr Pain Headache Rep. 2012 Oct;16(5):439-44. doi: 10.1007/s11916-012-0289-4.
PubMed 22836591Yu SH, Kim HJ. Electrophysiological characteristics according to activity level of myofascial trigger points. J Phys Ther Sci. 2015 Sep;27(9):2841-3. doi: 10.1589/jpts.27.2841. Epub 2015 Sep 30.
PubMed 26504306Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18.
PubMed 20961685Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. Nat Rev Rheumatol. 2010 Oct;6(10):599-606. doi: 10.1038/nrrheum.2010.107. Epub 2010 Jul 27.
PubMed 20664523Fernandez-de-las-Penas C, Cuadrado ML, Arendt-Nielsen L, Simons DG, Pareja JA. Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia. 2007 May;27(5):383-93. doi: 10.1111/j.1468-2982.2007.01295.x. Epub 2007 Mar 14.
PubMed 17359516Kim Y, Kim J, Shim JK, Suh DW, Yoon B. The hypoalgesic effect of remote tactile sensory modulation on the mechanical sensitivity of trigger points: A randomized controlled study. NeuroRehabilitation. 2014;35(3):607-14. doi: 10.3233/NRE-141156.
PubMed 25248449LaMotte RH, Lundberg LE, Torebjork HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol. 1992 Mar;448:749-64. doi: 10.1113/jphysiol.1992.sp019068.
PubMed 1593488Srbely JZ, Dickey JP, Bent LR, Lee D, Lowerison M. Capsaicin-induced central sensitization evokes segmental increases in trigger point sensitivity in humans. J Pain. 2010 Jul;11(7):636-43. doi: 10.1016/j.jpain.2009.10.005. Epub 2009 Dec 16.
PubMed 20015704Torebjork HE, Lundberg LE, LaMotte RH. Central changes in processing of mechanoreceptive input in capsaicin-induced secondary hyperalgesia in humans. J Physiol. 1992 Mar;448:765-80. doi: 10.1113/jphysiol.1992.sp019069.
PubMed 1593489
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quantitative Response of Healthy Muscle Following the Induction of Capsaicin
- ClinicalTrials.gov ID
- NCT03944889
- Acronym / sponsor ID
- QUROC / CapsaicinUltrasound
- Conditions
- Central Sensitisation
- Keywords
- MUAP- Motor Unit Action Potential, RMS- Root Mean Square, US-Ultrasound
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Toronto Rehabilitation InstituteUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 1 Jul 2020 (actual)
- Study completion
- 1 Dec 2020 (actual)
- First posted
- 10 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Central Sensitization is an aspect of chronic pain and is associated with over-excitability of the central nervous system. Central Sensitization normally presents itself with other chronic syndromes such as Myofascial Pain Syndrome, so it is difficult to separate the characteristics of the two. The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin, a chilli pepper extract, induces a regional change in ultrasound texture features of the targeted muscle, or the muscles in that are in close proximity. This regional change will be accompanied by electromyography (EMG) recordings to confirm the presence of abnormality. Topical capsaicin and injectable capsaicin will be applied at three different concentrations, 0ug(placebo effect),50ug and 100ug.
Research Questions:
Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles? Is this regional change confirmed by abnormality of motor unit firing rates or EMG amplitudes? Is the response dose dependent? Does the induced central sensitization cause a change in force steadiness?
Experimental Protocol:
The physician on site will apply surface and intramuscular EMG sensors to the trapezius. A goniometer will be placed on the subjects arm to detect position. Following this, an ultrasound image of the trapezius, supraspinatus and infraspinatus will be taken.The participant will perform an increasing and decreasing contraction.The subject will then have capsaicin injected into their trapezius or applied onto their skin. The exercise and measurements will then be repeated. The ultrasound will be acquired by the Sonosite ultrasound system. The EMG data will be acquired by the Delsys Trigno EMG system for the surface EMG and the Cadwell Sierra Wave system for the intramuscular EMG. The data will be processed through Delsys EMGworks software and MATLAB. Texture features of the pre and post injection ultrasound images will be compared. Decomposition of motor units will allow for the analysis of motor unit action potential firing rate and amplitudes. Analysis of force steadiness will also be calculated via the goniometer.
Overall, the findings from this study should present preliminary evidence to inform central sensitization's effects on regional muscle structure changes, functional changes and motor unit activity.
Detailed description
Myofascial pain syndrome (MPS) is a prevalent chronic pain disorder primarily characterized by myofascial trigger points (MTrP). There is limited knowledge on the pathophysiology and mechanisms underlying MTrP and its development. Ultrasound investigations that have been performed on trigger points can differentiate between active and latent trigger points, but have not characterized the central sensitization aspect of them. The electromyography (EMG) investigations of central sensitization that have been performed mostly use hypertonic saline to induce hyperalgesia, and have demonstrated conflicting results. Central sensitization has been proposed as the primary mechanism underlying MTrP development. Central sensitization is associated with hyperexcitability of neuronal responses to normal or noxious stimuli. There is a need for a study that quantifies regional central sensitization using ultrasound to measure the changing structure, and electromyography to measure specific motor unit activity responses in the muscle.
Purpose The purpose of this study is to determine whether sensitizing healthy muscle using capsaicin induces a change in the structural integrity of the affected muscle, and determine if the motor unit frequency and amplitudes change within that region. Central sensitization will be induced using topical capsaicin and injectable capsaicin at three different concentrations. This is an exploratory trial that aims to provide preliminary evidence on whether central sensitization is a direct cause of taut band and MTrP development.
Our specific research questions are followings:
- Does sensitization cause a significant regional change in the texture features of the targeted muscle or surrounding muscles?
- Does capsaicin induced sensitization elicit a change in motor unit action potential(MUAP) amplitude by approximately 20 to 25% within the region of experimentally induced central sensitization or in the region of texture feature changes? Our hypothesis for this portion of the study is that sensitization modifies the anterior horn cell activity which will be measured by the amplitude of the potentials.
- Does capsaicin induced sensitization elicit continuous electrical activity as observed in MTrPs? This tests the hypothesis that sensitization creates the presence of continuous low amplitude action potentials.
- Does capsaicin induced sensitization influence the rate of recruitment of motor units in the muscle within the region induced? Does this occur within the regions identified by the changes in texture features? The recruitment of motor units is normally expected to follow the Henneman size principle.[20-23] Our hypothesis for this portion of the study is that sensitization will cause an aberration in recruitment. If this is demonstrated, then there is modification of the normal processing at both dorsal and ventral horns of the spinal cord.
- Is there a location dependent EMG response to capsaicin induced sensitization? In other words, do the texture features or EMG responses from muscles that lie anatomically distant from the location of the site of intramuscular capsaicin injection have changes from their baseline calculations? This would test the hypothesis that type III and IV afferents have an influence on the anterior horn cells that lie distant to the ones that are supplying muscle fibers in the vicinity of the stimulated sensory afferents.
- Is there a dose dependent EMG response at motor units to capsaicin induced sensitization? Here, the hypothesis of causality will be assessed in a preliminary manner. If there is a relationship then further experiments that more thoroughly assess causality will be needed.
This proposed study is a single centered, factorial, randomized placebo-controlled trial with two independent variables, depth of capsaicin application(3 levels) and dose of capsaicin(3 levels), for a total of 6 treatment arms and three control groups.The first between groups variable will be topical capsaicin application, injectable(intrafascial) and injectable(intramuscular) capsaicin injection. Within each partition, there will be three treatments: control, 50 micrograms, 100 micrograms. The control group will receive a topical skin lotion that is inert and has no sensitization effect. An equal number of participants will be allocated to each of the six treatment groups using an electronic randomization generator. Block randomization will be used to ensure equal allotment into each group.
Capsaicin Application and Injection Capsaicin will be applied directly to the region of the innervation zone at the muscle belly to sensitize the neurons within the region of taut band development. Topical and intramuscular capsaicin will be used. The capsaicin formula will be compounded by a registered pharmacist. Topical capsaicin will be delivered in a cream and injectable capsaicin will be intermixed with saline prior to injection. The control group in the topical capsaicin arm will be treated with the cream base used during the experiment without added capsaicin and the injection arm will be injected with saline. A trained medical professional on the research team will apply the topical capsaicin or topical placebo treatments. The region of topical application will measure 5cm squared in the dermatome zone location to cover an area of approximately 25cm2. A trained physician in physical medicine and rehabilitation will deliver injectable capsaicin using a 27-gauge needle at the location of the superior fascia of the upper trapezius muscle with ultrasound guidance. Intramuscular capsaicin will also be injected using ultrasound guidance to avoid the superior or inferior fascia.
To confirm the presence of central sensitization, brush allodynia will be used to detect mechanical hyperalgesia outside the region of primary nociception. The size of the region of secondary hyperalgesia will be measured to characterize the extent of central sensitization. This will be accomplished using a tape measure and the perpendicular dimensions of the region of secondary hyperalgesia will be recorded in square centimeters.
Experimental Protocol The anatomical location for ultrasound probe and electrode placement will be identified for each participant. The ultrasound probe will be placed on 3 muscles: the trapezius, the supraspinatus, and the infraspinatus. Two ultrasonic pictures will be taken of each. The area will then be cleaned with alcohol and water. The Delsys Galileo sensor, and the intramuscular needle electrode will be placed directly on the trapezius' identified area. Participants will be asked to gently contract their trapezius muscle. They will be instructed to perform a gradually increasing contraction in isometric condition, in a controlled manner. They will hold this contraction at 30% of their maximal voluntary contraction, and then perform a gradually decreasing contraction to rest. This will be performed four times for each type of study intervention and before as well as after each intervention, namely topical control cream, topical capsaicin at 50ug and 100 ug, injection of the superior aspect of the superior fascia followed by intramuscular injection with these two concentrations of capsaicin. The placement of these latter will be verified by ultrasound guidance. The intramuscular needle will then be removed and participants will be bandaged and cared for appropriately by the expert physician performing the experiment. Participants will be re-examined to determine if there were any adverse effects from the experimental procedures. If any occurred, then these will be carefully managed by the medical members of the research team and recorded. Participants will be asked to remain at the lab for an additional 30 minutes to ensure they are well prior to leaving.
Ultrasound Analysis Texture analysis will be performed using MATLAB and the image and signal processing toolbox. Analyses will include first order parameters such as mean and standard deviation of the pixel level values, as well as second order parameters, which provide details on the spatial distribution of pixel values. These include co-occurance and run-length matrices, local binary pattern and blob analysis.
EMG Analysis The following parameters will be analyzed: the firing times and frequency of individual motor units, motor unit action potential amplitude and shapes, the root mean square value (RMS) of each channel and of the entire signal, the coefficient of variation for force steadiness, and the centroid of the EMG signal in the cranial-caudal and the medial-lateral directions. These procedures will be repeated for each contraction.
The results of this study should provide insight into the structural changes and motor changes at the region of sensitization, as well as in adjacent muscles.This will provide further insight as to whether structural changes are accompanied by motor changes within the same region, and inform further investigations into the pathophysiology of myofascial pain.
The full study protocol and statistical analysis plan is submitted in the documents section.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (participant)
- Number of arms
- 9
- Model description
- A single-centered, factorial, randomized, placebo-controlled trial with two independent variables (dosage and depth of application).
| Arm | Type | Receives |
|---|---|---|
| Placebo Topical | Placebo comparator | Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerPlacebo Cream, applied topically to trapezius muscle |
| Low Dose, Topical | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerCapsaicin Cream- low dosage, applied topically to trapezius |
| High Dose, Topical | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerCapsaicin Cream- higher dosage, applied topically to trapezius |
| Placebo, Intrafascial | Placebo comparator | Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection placebo(saline)- injected intrafascially into trapezius |
| Low Dose, Intrafacial | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection Capsaicin formulation low dose- injected intrafascially into trapezius |
| High Dose, Intrafascial | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection Capsaicin formulation higher dose- injected intrafascially into trapezius |
| Placebo, Intramuscular | Placebo comparator | Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection placebo (saline) - injected intramuscularly into trapezius |
| Low Dose, Intramuscular | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection Capsaicin formulation low dose - injected intramuscularly into trapezius |
| High Dose, Intramuscular | Active comparator | Drug: Capsaicin, Device: Delsys Trigno Galileo System, Device: Cadwell Sierra Wave, Device: Sonosite Ultrasound Machine, Device: GoniometerInjection Capsaicin formulation higher dose - injected intramuscularly into trapezius |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- healthy with no past medical history
- a visual analogue score below 3 indicating low pain severity, ideally who complain of no pain
- right or left handed
- normal body mass index
- have sufficient knowledge of the English language to provide informed consent and understand the protocols
Key exclusion criteria (7 listed)
- history of pain
- detectable myofascial trigger points upon physical examination
- history of pain related disturbances such as poor sleep
- cognitive disturbances, psychiatric disorders
- history of general medical disorder that may affect the outcome of the study such as diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CapsaicinCapsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution. | Drug | High Dose, Intrafascial, High Dose, Intramuscular, High Dose, Topical, Low Dose, Intrafacial, Low Dose, Intramuscular, Low Dose, Topical |
| Delsys Trigno Galileo SystemThis device is a wireless surface EMG device. | Device | High Dose, Intrafascial, High Dose, Intramuscular, High Dose, Topical, Low Dose, Intrafacial, Low Dose, Intramuscular, Low Dose, Topical, Placebo Topical, Placebo, Intrafascial, Placebo, Intramuscular |
| Cadwell Sierra WaveIntramuscular EMG recording machinery | Device | High Dose, Intrafascial, High Dose, Intramuscular, High Dose, Topical, Low Dose, Intrafacial, Low Dose, Intramuscular, Low Dose, Topical, Placebo Topical, Placebo, Intrafascial, Placebo, Intramuscular |
| Sonosite Ultrasound MachineUltrasound System | Device | High Dose, Intrafascial, High Dose, Intramuscular, High Dose, Topical, Low Dose, Intrafacial, Low Dose, Intramuscular, Low Dose, Topical, Placebo Topical, Placebo, Intrafascial, Placebo, Intramuscular |
| GoniometerA device to measure angular position | Device | High Dose, Intrafascial, High Dose, Intramuscular, High Dose, Topical, Low Dose, Intrafacial, Low Dose, Intramuscular, Low Dose, Topical, Placebo Topical, Placebo, Intrafascial, Placebo, Intramuscular |
Primary outcome
Motor Unit Action Potential Firing Rate
Time frame: up to 6 months
Firing rate will be determined using EMGworks software and compared with baseline firing rates.
Root Mean Square EMG values
Time frame: up to 6 months
Root mean square values will be compared with baseline values using EMGworks software.
Coefficient of Variation- Force steadiness
Time frame: up to 6 months
Force steadiness will be measured by the coefficient of variation (standard deviation/mean) using EMGworks software, validated through the goniometer measurements
Motor Unit Action Potential Amplitudes
Time frame: up to 6 months
Amplitudes will be measured from the overall amplitude difference from baseline for each motor unit using EMGworks software
Centroid of Frequency Spectrum
Time frame: up to 6 months
Centroid frequency will be measured and the frequency shift of the signal will be compared with baseline. Measured using EMGworks software
Texture Feature Analysis
Time frame: up to 6 months
91 features will be extracted using MATLAB, then a reduction of variables will be performed using principal component analysis. The experimental data will be compared with baseline results.
1 secondary outcome
Severity of pain
Time frame: up to 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2020.
- Background: PubMed 20607458Srbely JZ. New trends in the treatment and management of myofascial pain syndrome. Curr Pain Headache Rep. 2010 Oct;14(5):346-52. doi: 10.1007/s11916-010-0128-4.
- Background: PubMed 20870500Masuda T, Sadoyama T. Distribution of innervation zones in the human biceps brachii. J Electromyogr Kinesiol. 1991 Jun;1(2):107-15. doi: 10.1016/1050-6411(91)90004-O.
- Background: PubMed 23758854Barbero M, Cescon C, Tettamanti A, Leggero V, Macmillan F, Coutts F, Gatti R. Myofascial trigger points and innervation zone locations in upper trapezius muscles. BMC Musculoskelet Disord. 2013 Jun 8;14:179. doi: 10.1186/1471-2474-14-179.
- Background: PubMed 69288Melzack R, Stillwell DM, Fox EJ. Trigger points and acupuncture points for pain: correlations and implications. Pain. 1977 Feb;3(1):3-23. doi: 10.1016/0304-3959(77)90032-X.
- Background: PubMed 9685106Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points. Arch Phys Med Rehabil. 1998 Jul;79(7):863-72. doi: 10.1016/s0003-9993(98)90371-9.
- Background: PubMed 15509461Gerwin RD, Dommerholt J, Shah JP. An expansion of Simons' integrated hypothesis of trigger point formation. Curr Pain Headache Rep. 2004 Dec;8(6):468-75. doi: 10.1007/s11916-004-0069-x.
- Background: PubMed 22836591Bron C, Dommerholt JD. Etiology of myofascial trigger points. Curr Pain Headache Rep. 2012 Oct;16(5):439-44. doi: 10.1007/s11916-012-0289-4.
- Background: PubMed 26504306Yu SH, Kim HJ. Electrophysiological characteristics according to activity level of myofascial trigger points. J Phys Ther Sci. 2015 Sep;27(9):2841-3. doi: 10.1589/jpts.27.2841. Epub 2015 Sep 30.
- Background: PubMed 20961685Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-S15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18.
- Background: PubMed 20664523Graven-Nielsen T, Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. Nat Rev Rheumatol. 2010 Oct;6(10):599-606. doi: 10.1038/nrrheum.2010.107. Epub 2010 Jul 27.
- Background: PubMed 17359516Fernandez-de-las-Penas C, Cuadrado ML, Arendt-Nielsen L, Simons DG, Pareja JA. Myofascial trigger points and sensitization: an updated pain model for tension-type headache. Cephalalgia. 2007 May;27(5):383-93. doi: 10.1111/j.1468-2982.2007.01295.x. Epub 2007 Mar 14.
- Background: PubMed 25248449Kim Y, Kim J, Shim JK, Suh DW, Yoon B. The hypoalgesic effect of remote tactile sensory modulation on the mechanical sensitivity of trigger points: A randomized controlled study. NeuroRehabilitation. 2014;35(3):607-14. doi: 10.3233/NRE-141156.
- Individual participant dataSharing planned: No. The University Health Network has a high importance on patient confidentiality. For ethics approval, this was complied with these standards, upholding the patient confidentiality standard at UHN.
Related trials for Central Sensitisation
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Recruiting
Aquatic Exercise in Patients With Knee Osteoarthritis
Central Sensitization, Knee Osteoarthristis
Recruiting
Device-Assisted Balance Training for People With Shoulder Impingement
Shoulder
Not yet recruitingObservational study
Agreement Between CSI and IASP Pain Classification in Chronic Cervical Myofascial Pain
Myofascial Pain Syndrome - Neck
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dinesh M Kumbahre, MD,PhD principal investigator
Toronto Rehabilitation Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Capsaicin, Delsys Trigno Galileo System and Cadwell Sierra Wave in people with Central Sensitisation, run by Toronto Rehabilitation Institute at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor Unit Action Potential Firing Rate (time frame: up to 6 months). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03944889, which also lists 45 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2020.